Restless Legs Syndrome

PLEASANTON, Calif., Jan. 16, 2024 /PRNewswire/ -- Noctrix Health, Inc. announced today that it has closed a $40M Series C financing round led by Sectoral Asset Management with participation from other new investors Angelini Ventures, ResMed, and Asahi Kasei Corporation with strong support from insiders including OrbiMed and Treo Ventures. This infusion of capital will propel the advancement of Nidra™ Tonic Motor Activation (TOMAC) therapy towards its eagerly anticipated launch in the US market. Nidra™, a revolutionary new device, stands as the first and only approved treatment for drug-refractory Restless Legs Syndrome (RLS), a chronic condition that has debilitating impacts on sleep and quality of life of millions of adults worldwide. Continue Reading Nidra TOMAC therapy The Nidra™ Tonic Motor Activation therapy is a clinically validated treatment indicated for reducing the symptoms of RLS and improving sleep quality in adults refractory to medications and was granted a De Novo authorization by the US Food and Drug Administration (FDA) in April 2023 after receiving a Breakthrough Device Designation from the agency in 2020. Noctrix Health Founder and CEO, Shri Raghunathan, expressed his excitement at the successful funding round, stating, "We are thrilled to welcome Sectoral Asset Management and other new investors to this esteemed group of partners. This significant milestone, coupled with unwavering support from our existing investors, reflects our shared commitment to establishing a new standard of care for RLS. I extend my gratitude to our dedicated team for their hard work and am humbled by the overwhelming support received." Michael Sjöström, co-founder, and Partner at Sectoral Asset Management, shared his enthusiasm, stating, "I am honored to join Noctrix Health on its journey in redefining RLS treatment. We believe in the transformative potential of TOMAC therapy and look forward to contributing to the company's continued success." "The strength of Noctrix Health's clinical data combined with the tremendous unmet need underscore the importance of bringing TOMAC therapy to patients with RLS," said Evan Caplan, Principal at OrbiMed. "We have seen how well the team has executed and are excited to continue partnering with them as the company initiates commercialization." "Treo Ventures is thrilled to continue supporting Noctrix Health. This significant financing will allow the company to reach millions of patients with RLS. TOMAC therapy is a patient-friendly, highly effective, non-pharmacologic innovation for patients unhappy with current solutions who need better treatment options," commented Tracy Pappas, General Partner, Treo Ventures. Noctrix Health has experienced a banner year in 2023, marked by the FDA marketing authorization of TOMAC therapy, followed by several key publications including a recent study demonstrating TOMAC therapy's efficacy in reducing opioid use in patients with RLS, further reinforcing its potential impact on patient outcomes. About Nidra™ TOMAC Therapy The Nidra™ Tonic Motor Activation (TOMAC) system is the first and only non-pharmacologic, wearable treatment intended to reduce symptoms of primary moderate-severe Restless Legs Syndrome (RLS) and improve sleep quality in adults refractory to medications. It is available in the US by prescription only. For more information on availability or clinical and important safety information, please visit . About Noctrix Health, Inc. Noctrix Health is a medical device company committed to developing clinically validated breakthrough medical technologies that improve the quality of life for patients with chronic conditions. For enquiries contact [email protected]. SOURCE Noctrix Health, Inc

The service aims to provide factual information about sleep disorders, practical suggestions, and support and guidance in navigating the healthcare landscape LOS ANGELES, Dec. 6, 2023 /PRNewswire/ -- Project Sleep, a nonprofit dedicated to raising awareness of sleep health, sleep equity, and sleep disorders, is thrilled to announce the official launch of the Sleep Helpline™, a new, professionally-staffed national helpline providing timely and trusted resources to help individuals navigate sleep issues and sleep disorders at every step of the journey. Continue Reading The Sleep Helpline™ is here to help you at every step of your journey navigating sleep issues and sleep disorders. "An estimated 50-70 million Americans live with a chronic sleep disorder, yet the majority are undiagnosed," said Julie Flygare, JD, President & CEO of Project Sleep. "We know that the path to finding accurate sleep disorder diagnosis, treatment, and support is often long, lonely, and inefficient. This is why the new Sleep Helpline will meet people where they are in moments of uncertainty, to provide free and personalized one-to-one support and resources." The Sleep Helpline welcomes anyone looking for information about sleep disorders to reach out, including those uncertain if they might have a sleep-related condition, those diagnosed with a sleep condition, along with loved ones, caregivers, healthcare providers, educators, and social workers. "The Sleep Helpline will be a tremendous help to all of us in the sleep community who care for patients," said Michael A. Grandner, PhD MTR, Director of the Sleep and Health Research Program at the University of Arizona, and Member of Project Sleep's Expert Advisory Board. "Especially in our busy society where sleep is undervalued and sleep disorders are often overlooked, this new resource led by a respected nonprofit like Project Sleep will empower individuals to understand their sleep symptoms, guide them as they seek the right healthcare attention sooner, and support them as their experiences and concerns evolve over time." There are a wide variety of common and serious sleep disorders, including breathing disorders such as obstructive sleep apnea, central sleep apnea, and upper-airway resistance syndrome; hypersomnias such as narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome; insomnia disorder; movement disorders such as restless legs syndrome and periodic limb movements; parasomnias such as REM sleep behavior disorder and sleepwalking; and sleep-wake disorders such as Non-24 and shift work disorder. "As a person living with a sleep disorder myself, I know first-hand that there are times when you are not sure where to turn or who to talk to," added Julie Flygare. "We want you to know that you are not alone – Project Sleep's Sleep Helpline is here to address your questions and figure out next steps together." Special thanks to Jazz Pharmaceuticals and Harmony Biosciences for generously providing sponsorship funding to support the development of Project Sleep's new Sleep Helpline to support millions of people facing sleep issues and sleep disorders. The Sleep Helpline officially launches today, Dec. 6, 2023, with Resource Specialists available Monday through Friday, 9:00 a.m. to 4:00 p.m. (Eastern Time). Individuals can reach out to the Sleep Helpline via phone at 1-800-819-2043, or by email at [email protected]. Learn more at: project-sleep.com/helpline. About Project Sleep Project Sleep is a 501(c)(3) non-profit organization dedicated to raising awareness about sleep health, sleep equity, and sleep disorders. The organization's programming includes the Rising Voices℠ advocate leadership program, the Sleep Helpline™, the Sleep Advocacy Program, the Sleep Equity Initiative, Project Sleep's Podcast, the Jack & Julie Narcolepsy Scholarship, the Narcolepsy Nerd Alert series, World Narcolepsy Day, and the Sleep In. Follow Project Sleep on Facebook, Instagram, Twitter and LinkedIn, or visit their website at project-sleep.com. Media inquiries: [email protected] SOURCE Project Sleep

BioAdaptives’ SleepEZ™ Supplement Delivers Natural Sleep Support Leading Sleep Experts Meet at the World Sleep Congress This Week to Discuss Latest Breakthroughs Chronic Insomnia Affects an Estimated 30% of the World’s Population LAS VEGAS, NV, Oct. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTC: BDPT), a leading formulator and distributor of innovative, all-natural dietary supplements, is targeting a multi-billion dollar industry with its popular, natural sleep supplement, SleepEZ™. Chronic insomnia affects approximately 30% of the world’s population, including 50 to 70 million Americans who suffer from sleep disorders, which include insomnia, restless legs syndrome, narcolepsy and sleep apnea. Sleep plays a vital role in good health, and this week, the world’s foremost experts in sleep medicine have converged in Rio de Janeiro at the World Sleep Congress to discuss the latest developments across clinical and basic sleep and circadian research. Edward Jacobs, M.D., BioAdaptives CEO, said, “BioAdaptives’ mission is to improve health and wellness for humans and animals through natural plant-based products, and we are proud to be at the forefront of delivering a natural sleep supplement to people living with sleep disorders. “Difficulty sleeping is a common but neglected symptom that can have serious effects on health. Better quality sleep enables the body to boost immunity, reduce stress, and the risk of chronic diseases. Our SleepEZ™ supplement works with the circadian rhythm to promote restful and sustained sleep without the morning hangover drowsiness, an unwanted feature of many sleep aids. “Additionally, our focus is always on delivering long term value for shareholders. Sleep EZ™ is one of BioAdaptives’ best selling products and part of our highly successful range of natural supplements aimed at optimizing pain relief, immune system defense and resistance to stress. We are targeting a slice of the global sleep aid market which was valued at $59 billion in 2020 and is projected to reach $111 billion by 2023.” About SleepEZ™ SleepEZ™ is an all-natural supplement formula with origins in Traditional Chinese Medicine (TCM) featuring the optimal dose of high-quality ingredients. The most important component is XylariaⓇ (WulinshenPrimeTM), a proprietary extract from Xylaria nigripes. Published in vivo and human clinical trials have shown XylariaⓇ has mild to moderate effect in improving sleep quality, promoting relaxation, and elevating mood, but none of the side effects of prescription medications. XylariaⓇ reduces the amount of time taken to fall asleep (sleep latency) and also produces a calming effect due to Gamma-aminobutyric acid (GABA) and other synergetic constituents. Additional ingredients include Lemon balm (Melissa officinalis), which encourages relaxation and reduces stress, Passionflower extract (Passiflora) which helps decrease anxiety and insomnia, and Chinese date (Zizyphus jujuba), which contains saponin, a natural sleep promoter. About BioAdaptives, Inc. BioAdaptives, Inc. develops and distributes natural plant- and algal-based products that improve health and wellness for humans and animals, with an emphasis on optimizing pain relief, antiviral activity, and immune system defense; resistance to stress; endurance; recovery from injury, illness, and exercise; and anti-aging properties. The Company’s current dietary supplement formulations are carefully selected from the best sources around the world and utilize proprietary methods of enhancing the bioavailability of nutrients. BioAdaptives’ current product line includes PrimiLungs™, PluriPain®, SleepEZ™, MindnMemory™ and Cell Rejuven™ for humans. The Company’s products for horses and dogs have also demonstrated increased general health, competitive performance enhancement, rejuvenation effects, and pain relief, as well as providing improvements in appearance. BioAdaptives’ wholly owned subsidiary, LiveStock Impact, Inc markets Canine Regen All In One™, Equine All In One™ and Equine All In One Plus™ for dogs and horses. LiveStock Impact, Inc is also positioned to develop and market botanical drugs. BioAdaptives’ common shares trade in the OTC market under the symbol BDPT. It has over 13,000 current shareholders. None of the statements about the Company’s products have been approved by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Additional information can be found at www.shopbioadaptives.com or in our SEC filings at https://www.sec.gov/cgi-bin/browse-edgar?company=bioadaptives&owner=exclude&action=getcompany Safe Harbor Statement This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date after the date of this press release. Contact Investor Relations BioAdaptives, Inc. (702) 659-8829 info@bioadaptives.com